Lumenis: Ophthalmology
 
Selecta II Glaucoma Laser System
Selecta II Glaucoma Laser System
The Selecta II Glaucoma Laser System can be applied to the following conditions:

Assured Compliance

The Selecta II Glaucoma Laser System is a Q-switched 532 Nd:YAG laser used in a procedure called Selective Laser Trabeculoplasty (SLT). Cleared by the U.S. Food and Drug Administration in 2001, this new system features a patented technique for performing trabeculoplasty in patients with open-angle glaucoma. It selectively targets pigmented cells and increases fluid output, lowering intraocular pressure.

The Selecta II is equipped with a Q-switch that produces a 3-nanosecond high-energy beam of light, which induces the same cell replacement mechanism as traditional argon laser therapy (ALT), but without the burn. The short pulse of the laser does not allow time for heat to spread to other cells. SLT delivers just enough energy to the trabecular meshwork (TM) to target specific melanin-rich cells. This avoids thermal damage and scarring to adjacent non-melanin cells.

 
Trabecular meshwork
tissue after SLT
  Trabecular meshwork
tissue after ALT

"SLT appears to cause no coagulative damage to the human TM, and less structural damage to the TM compared with ALT." Theresa R. Kramer, M.D., Associate Professor of Ophthalmology, Emory University, Atlanta, Georgia

A 'Drop' of Light

  • Q-switch produces short pulses of low energy laser light
  • Selectively targets pigmented cells, increasing fluid outflow
  • Eliminates burns that scar trabecular meshwork
  • Economical and efficient, treatment is performed in the physician's office
  • Provides economic benefits for the patient and physician. Laser tabeculoplasty is a Medicare covered procedure and is reimbursable under CPT code 65855

"SLT will have a significant impact on glaucoma treatment, as well as the field of medicine." Carmen A. Puliafito, MD, Ocular Surgery News, Professor of Ophthalmology and Health Management, Tufts University School of Medicine

Excellent Clinical Results

Scientific proof of its mechanisms, along with successful results showing clinical effectiveness in lowering IOP with SLT has been ongoing in the United States for five years.

Details

 

Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner.

Downloads





Sign up to receive the latest product, training and update information.
Email
Zip Code


©2008 Lumenis Ophthalmology | Terms of Use | Legal Notice | Privacy Statement | Trademarks